Mesoblast Limited (NASDAQ:MESO) saw unusually large options trading on Monday. Stock investors acquired 6,669 call options on the stock. This represents an increase of approximately 1,144% compared to the average volume of 536 call options.
Mesoblast stock opened at $7.41 on Tuesday. Mesoblast has a 52 week low of $7.18 and a 52 week high of $21.28. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.10. The stock has a market cap of $961.37 million, a P/E ratio of -8.42 and a beta of 3.71. The stock has a 50 day moving average of $8.58 and a 200-day moving average of $10.39.
Mesoblast (NASDAQ:MESO) last released its earnings results on Tuesday, March 2nd. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.12). Mesoblast had a negative return on equity of 18.69% and a negative net margin of 591.00%. The company had revenue of $2.24 million during the quarter, compared to the consensus estimate of $2.14 million. As a group, equities analysts predict that Mesoblast will post -0.63 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in MESO. Citigroup Inc. grew its position in shares of Mesoblast by 3,152.6% in the 4th quarter. Citigroup Inc. now owns 61,800 shares of the company’s stock worth $524,000 after acquiring an additional 59,900 shares in the last quarter. FNY Investment Advisers LLC increased its stake in Mesoblast by 100.0% during the fourth quarter. FNY Investment Advisers LLC now owns 69,197 shares of the company’s stock valued at $587,000 after purchasing an additional 34,597 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Mesoblast during the fourth quarter worth $290,000. Princeton Capital Management LLC lifted its position in shares of Mesoblast by 17.3% in the 4th quarter. Princeton Capital Management LLC now owns 173,213 shares of the company’s stock worth $1,471,000 after buying an additional 25,555 shares during the last quarter. Finally, Game Plan Financial Advisors LLC acquired a new position in shares of Mesoblast in the 4th quarter valued at about $141,000. Hedge funds and other institutional investors own 2.80% of the company’s stock.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells.
Recommended Story: Book Value Per Share in Stock Trading
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.